Form 4: Acadia Pharmaceuticals Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Elizabeth H.Z. Thompson, EVP, Head of Research & Dev of Acadia Pharmaceuticals Inc, sold 16,558 shares of common stock on July 29, 2026.

Summary

  • Option exercise/conversion: acquired 32,272 Common Stock on July 29, 2026; holds 35,552 after (Direct).
  • Open-market sale: disposed of 16,508 Common Stock at $26.13 ($431,354) on July 30, 2026; holds 19,044 after (Direct).
  • Open-market sale: disposed of 50 Common Stock at $26.17 ($1,308) on July 30, 2026; holds 18,994 after (Direct).
  • Option exercise/conversion: disposed of 32,272 Restricted Stock Units on July 29, 2026; holds 32,272 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $432,663 of stock on the open market.

Insider Transactions

Elizabeth H.Z. Thompson — Officer (EVP, Head of Research & Dev)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-29Option exercise/conversionCommon Stock32,272——35,552
2026-07-30Open-market saleCommon Stock16,508$26$431.4K19,044
2026-07-30Open-market saleCommon Stock50$26$1.3K18,994
2026-07-29Option exercise/conversionRestricted Stock Units32,272——32,272

Key Dates

DateDescription
2026-07-29Option exercise/conversion (32,272 shares)
2026-07-30Open-market sale (16,508 shares)
2026-07-30Open-market sale (50 shares)
2026-07-29Option exercise/conversion (32,272 shares)

Keywords

insider transaction, Form 4, ACAD, ACADIA PHARMACEUTICALS INC, bearish, Elizabeth H.Z. Thompson

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.